"A lot of important innovative progress has been demonstrated at GA in the past year, and I am pleased to give an update on all the product development results we have achieved during 2023. This development strengthens our position as a key player in the microbiome diagnostic market and a driver in microbiome diagnostic testing. We are now looking ahead to the coming year, ready to continue our efforts to reach new value-adding milestones and position the Company as a leader in microbiome diagnostic testing."
Strengthen the GA-map® Dysbiosis Test offering to its customers
GA continues its strategy of making microbiome diagnostics available and affordable for any molecular lab, developing innovations to increase the attractiveness of the Company's products. Recently, significant progress has been made on some key user aspects of the GA-map® Dysbiosis Test. The tests now have an extended shelf life of 18 months, surpassing the previous shelf life of 12 months. The reagent kits, once limited to three uses, are now optimized for up to five uses before disposal. These improvements underline the excellent quality of the GA-map® and result in an even more user-friendly and cost-effective product, further strengthening the customer offering and cementing GA as a pioneer in microbiome diagnostics.
Innovative cloud-based software solutions
During the year, the Company has also made a giant leap by launching its cloud-based software solution for the GA-map® platform, and its cloud-based training and onboarding software. The cloud-based GA-map® software enables the lab to upload raw data and instantly receive patient results which are presented in a detailed multilingual result report, all compared to a healthy reference microbiome.
Progress in Chinese cooperation project
Early last year, GA agreed with
GA-map® Discovery - for research
As a part of our focus on microbiome research, GA is thrilled to have been able to complete the launch of the GA-map® Discovery, as communicated in
A new companion diagnostic marker
During the year, GA has been occupied with completing a pilot project for a Pharma company on a new companion diagnostic test, as communicated in
New marker for IBD
The development of a new diagnostic test for inflammatory bowel disease (IBD) is continuing as planned, with significant sample cohorts being analyzed. The objective is to develop a diagnostic test that utilizes the profile of a microbiome test to predict the disease course of ulcerative colitis (UC) patients, which will enable specialists to facilitate personalized treatments. GA receives significant grant funding for this project and is collaborating with the
For further information, please contact:
E-mail: rh@genetic-analysis.com
About Genetic Analysis:
For more general information: www.genetic-analysis.com
Stay updated on GA and sign up for more investor-related information: https://www.genetic-analysis.com/subscriptions/
Interested in reading more about GA's products? Please visit ga-map.com
https://news.cision.com/genetic-analysis-as/r/genetic-analysis-summarizes-this-year-s-product-development-activities-and-looks-ahead-to-2024,c3892540
https://mb.cision.com/Public/20846/3892540/873467ea9e7798a3.pdf
(c) 2023 Cision. All rights reserved., source